Axogen, Inc. Q3 FY2026 earnings call

• Revenue Growth & Financial Leverage: Revenue growth driven by unit volume and adoption across all markets. GAAP net income was $2.3 million; adjusted net income was $13.1 million. Ended quarter with $350 million in cash.
• Market Development (Breast): Breast nerve reconstruction is gaining traction as resensation becomes part of standard care. Active breast accounts rose >95% YoY to ~485, and active surgeons rose >140 YoY to ~590. Finalized 2026 surgeon training programs for >50 plastic surgeons.
• Market Development (Extremities/OMF/H&N): Double-digit growth driven by account expansion and activation of high-potential accounts. Mandible reconstruction algorithm adoption and oncologic procedures (neck dissections) drove momentum.
• Commercial Expansion: Expanded sales force significantly. Breast team now has 31 reps (+10); Extremities/OMF/H&N team has 132 reps (+15) and 15 regional directors (+5).
• Standard of Care & Coverage: Achieved near-universal commercial payer coverage (~96% of covered lives in US). Elevance removed utilization management criteria for gap length in August. Aetna extended coverage for gaps ≤30mm in upper extremity; company working to resolve remaining restrictions.
• Clinical Evidence: MATCH study published showing AVANCE motor recovery comparable to autograft. Nerve Restore study enrolled first patient. EMBRACE study startup underway for breast sensory recovery evidence.
• Innovation & BioCircuit Acquisition: Completed acquisition of BioCircuit on Oct 1, adding NervTape as a sixth product. NervTape targets direct repair (40-50% of transected nerve procedures) and large gap repairs. Sales assumed by Axiogen’s direct organization.
• Prostate Strategy: Validated clinical need and safety profile (>220 patients treated, no complications). ~80% achieved expected erectile function recovery at 6+ months. Market development planned for 2027 launch.

Total revenue was $75.8 million, up 26.2% year-over-year. Avance constituted 64% of total revenue (up from ~60% in 2025). Breast revenue grew >50% year-over-year, while Extremities, OMF, and Head & Neck combined grew 10.7%. Gross margin was 74.8% (down from 76.6% a year ago but up from 72.7% in Q2 2026). Adjusted EBITDA was $13.4 million with a margin of 17.7%, up from 15.4% in the prior year period.

• Full Year 2026 Revenue: Revised upward to at least $290 million, implying organic growth of at least 26% ($283 million excluding BioCircuit contribution of ≥$7 million).
• Gross Margin: Expecting full-year gross margin of at least 73%. Note that fourth-quarter gross margin may be lower than Q2 due to production plan adjustments for long-length Avance products; yield improvements will lag.
• Free Cash Flow: Expect positive free cash flow for the full year.
• 2027 Outlook: No formal guidance provided yet. Informally expect 2027 gross margins to be similar to 2026 levels, pending pricing and yield initiatives.

• Gross Margin Pressure: Potential negative impact on Q4 and full-year 2026 gross margins from purchase accounting adjustments to BioCircuit inventory value step-up.
• Integration Disruption: BioCircuit revenue guidance contemplates some level of integration or disruption risk.
• Reimbursement Restrictions: Aetna’s new policy limits coverage to short-to-medium sensory nerve gaps (≤30mm), requiring ongoing collaboration with surgeons to resolve and expand coverage.
• Production Alignment: Need to align production plans with increased demand for long-length Avance products, which may temporarily suppress margins before yield improvements take effect.

Q: Analyst asked about breast penetration rates and drivers of growth (new accounts vs. existing utilization). / A: Management stated penetration is approx. 11%. Growth is driven by 'same-store' productivity increases as surgeons adopt resensation as standard of care, leading to referral network expansion and adoption by other surgeons within the same account, alongside new account additions. This infrastructure supports multi-year growth expectations.

Q: Analyst asked if the projected $34 million in NerveTape sales next year is incremental or cannibalistic to existing products like AXAguard connectors. / A: CFO confirmed that the $34 million figure is fully incremental, net of any cannibalization. The company models cannibalization assumptions internally but guides on organic growth. Connector usage will persist for specific procedures, while NerveTape targets larger gaps and direct repairs.

Q: Analyst asked about the biggest growth lever for NerveTape: direct repair, increased utilization in existing cases, or expanding surgeon population via ease of use. / A: CEO stated it is 'all of the above.' NerveTape removes barriers by simplifying procedures without sacrificing effectiveness. Key opportunities include enabling non-microsurgical trained surgeons to perform repairs, accelerating adoption in OMF/breast, and capturing the direct repair market where previous tools lacked a superior value proposition.

Q: Analyst asked about prostate targeting strategy regarding the 110,000 annual robotic prostatectomies. / A: Management clarified they will not target all centers initially. The launch strategy focuses on academic centers, high-volume centers, and facilities performing a mix of neurolateral/bilateral reconstructions and nerve-sparing procedures. Detailed targeting algorithms are being developed.

Q: Analyst asked about Q4 core market growth acceleration (implied ~27% organic growth) and sales force hiring pace. / A: CEO attributed growth to fundamental footprint expansion (more reps, more accounts, deeper penetration). CFO noted Q4 growth follows normal historical seasonality without a large sequential step-up. Management confirmed continued headcount additions into 2027 to support this expansion, ensuring profitability is maintained.